BioNTech Yönetim

Yönetim kriter kontrolleri 4/4

BioNTech CEO'su Ugur Sahin, Jan2008 tarihinde atandı, in görev süresi 16.83 yıldır. in toplam yıllık tazminatı € 3.06M olup, şirket hissesi ve opsiyonları dahil olmak üzere 22.9% maaş ve 77.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 17.23% ine doğrudan sahiptir ve bu hisseler MX$ 86.10B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 4.6 yıldır.

Anahtar bilgiler

Ugur Sahin

İcra Kurulu Başkanı

€3.1m

Toplam tazminat

CEO maaş yüzdesi	22.9%
CEO görev süresi	16.8yrs
CEO sahipliği	17.2%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	4.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Ugur Sahin'un ücretlendirmesi BioNTech'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-€467m
Jun 30 2024	n/a	n/a	-€504m
Mar 31 2024	n/a	n/a	€113m
Dec 31 2023	€3m	€700k	€930m
Sep 30 2023	n/a	n/a	€3b
Jun 30 2023	n/a	n/a	€4b
Mar 31 2023	n/a	n/a	€6b
Dec 31 2022	€6m	€360k	€9b
Sep 30 2022	n/a	n/a	€10b
Jun 30 2022	n/a	n/a	€12b
Mar 31 2022	n/a	n/a	€13b
Dec 31 2021	€12m	€360k	€10b
Sep 30 2021	n/a	n/a	€7b
Jun 30 2021	n/a	n/a	€4b
Mar 31 2021	n/a	n/a	€1b
Dec 31 2020	€17m	€360k	€15m
Sep 30 2020	n/a	n/a	-€410m
Jun 30 2020	n/a	n/a	-€230m
Mar 31 2020	n/a	n/a	-€192m
Dec 31 2019	€7m	€311k	-€179m
Sep 30 2019	n/a	n/a	-€122m
Jun 30 2019	n/a	n/a	-€116m
Mar 31 2019	n/a	n/a	-€77m
Dec 31 2018	€653k	€210k	-€48m

Tazminat ve Piyasa: Ugur 'nin toplam tazminatı ($USD 3.20M ), MX pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.71M ).

Tazminat ve Kazançlar: Ugur 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Ugur Sahin (59 yo)

16.8yrs

Görev süresi

€3,056,000

Tazminat

Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ugur Sahin	Co-Founder	16.8yrs	€3.06m	17.23% MX$ 86.1b
Ozlem Tureci	Co-Founder	6.8yrs	€814.00k	0.38% MX$ 1.9b
Jens Holstein	CFO & Member of Management Board	3.3yrs	€1.32m	0.00068% MX$ 3.4m
Sierk Poetting	MD, COO & Member of Management Board	10.8yrs	€821.00k	0.31% MX$ 1.6b
Ryan Richardson	Chief Strategy Officer	4.8yrs	€1.41m	0.0061% MX$ 30.6m
James Timothy Ryan	Chief Legal & Business Officer & Member of the Management Board	1.2yrs	€848.00k	Veri yok
Sean Marett	Executive Officer	less than a year	€133.00k	0.34% MX$ 1.7b
Lisa Birringer	Senior Vice President of Global Financial Reporting & Accounting	less than a year	Veri yok	Veri yok
Zach Taylor	Senior Vice President of Corporate Development & Strategy	less than a year	Veri yok	Veri yok
Katalin Kariko	Senior VP & External Consultant for RNA Protein Replacement Therapies	no data	Veri yok	Veri yok
Oliver Henning	Senior Vice President of Operations	no data	Veri yok	Veri yok
Sebastian Kreiter	Senior Vice President of Immunotherapy & Preclinical Research	no data	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: BNTX N 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rudolf Staudigl	Supervisory Board Member	2.4yrs	€90.00k	0.00017% MX$ 849.8k
Ulrich Wandschneider	Independent Deputy Chairman Supervisory Board	6.8yrs	€114.00k	Veri yok
Michael Motschmann	Independent Supervisory Board Member	16.8yrs	€80.00k	Veri yok
Helmut Jeggle	Independent Supervisory Board Chairman	16.8yrs	€226.00k	0.14% MX$ 692.9m
Nicola Blackwood	Member of Supervisory Board	1.5yrs	€46.00k	Veri yok
Anja Morawietz	Supervisory Board Member	2.4yrs	€105.00k	0.00010% MX$ 499.9k

4.6yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BNTX N 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.6 yıldır).

BioNTech Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

Recent updates

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

Third quarter 2024 earnings released: EPS: €0.82 (vs €0.67 in 3Q 2023)

New major risk - Revenue and earnings growth

BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024

BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

New major risk - Revenue and earnings growth

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbH

Second quarter 2024 earnings released: €3.36 loss per share (vs €0.79 loss in 2Q 2023)

BioNTech SE Reiterates Earnings Guidance for the Year 2024

BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: €1.31 loss per share (vs €2.07 profit in 1Q 2023)

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: €3.87 (vs €38.78 in FY 2022)

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

New minor risk - Shareholder dilution

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Third quarter 2023 earnings released: EPS: €0.67 (vs €7.43 in 3Q 2022)

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023

Second quarter 2023 earnings released: €0.79 loss per share (vs €6.86 profit in 2Q 2022)

BioNTech SE acquired remaining stake in InstaDeep Ltd for approximately £430 million.

BioNTech SE to Report Q2, 2023 Results on Aug 07, 2023

BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

BioNTech SE Provides Revenue Guidance for the Full Year 2023

Full year 2022 earnings released: EPS: €38.78 (vs €42.18 in FY 2021)

BioNTech SE Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

BioNTech SE Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Investor sentiment improved over the past week

Pfizer and BioNTech SE Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age

BioNTech SE and Pfizer Inc. Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine in Children Under 5 years

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

Pfizer Inc. and BioNTech SE Advances Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T Cell Responses and Duration of Protection

Pfizer and Biontech Receive Positive Chmp Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

Third quarter 2022 earnings released: EPS: €7.43 (vs €13.14 in 3Q 2021)

BioNTech SE Se Revises Its Earnings Guidance for the Full Year 2022

Pfizer Inc. and BioNTech SE Announces Updated Clinical Data for Omicron Ba.4/Ba.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Pfizer and Biontech Receive Positive CHMP Opinion for Comirnaty® in Children 6 Months to Less Than 5 Years in the European Union

Pfizer and BioNTech Announce Positive Early Data from Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Canada ULC and BioNTech SE's Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Individuals 12 Years of Age and Older

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Inc. and BioNTech SE Receive Positive Chmp Opinion for Conversion of Comirnaty® Conditional Marketing Authorization to Full Marketing Authorization in the European Union

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster in European Union

Biontech Presents Encouraging Phase 1/2 Follow-Up Data for Car-T Candidate Bnt211 in Hard-To-Treat Solid Tumors At ESMO

Pfizer Inc. and BioNTech SE Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months Through 4 Years of Age

Pfizer and Biontech Submits Application to U.S. FDA for Emergency Use Authorization of Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine

BioNTech Reiterates Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: EPS: €6.88 (vs €11.42 in 2Q 2021)